Histopathologic Diagnosis in Surgical Oncology

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 875

Special Issue Editor


E-Mail Website
Guest Editor
Pathology Unit, Ospedale Maggiore, 40139 Bologna, Italy
Interests: clinical pathology; endocrine; molecular

Special Issue Information

Dear Colleagues,

In the field of surgical oncology, histopathologic diagnosis plays a pivotal role in guiding clinical decisions, ensuring accurate treatment plans, and, ultimately, optimizing patient outcomes. Immunohistochemistry, molecular diagnostics, and digital pathology have revolutionized our ability to subtype tumors, predict patient responses, and enhance diagnostic accuracy.

Histopathology, the study of microscopic changes in tissue resulting from disease, is a cornerstone of cancer diagnosis. Surgical oncologists rely heavily on histopathologic reports to determine the type, grade, and extent of a tumor, as well as to assess the presence of metastatic disease. These reports are often the deciding factor in determining whether a patient receives surgical resection, radiation therapy, chemotherapy, or a combination of these modalities.

This Special Issue aims to improve our knowledge of the latest progress in histopathologic diagnosis in surgical oncology, providing valuable insights for medical professionals and researchers. In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

Dr. Francesca Ambrosi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunohistochemistry
  • histopathology
  • molecular diagnostics
  • digital pathology
  • biomarkers
  • surgical tumor

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 4492 KiB  
Article
Intra-Tumoral Lymphocytic Infiltration Is Associated with Favorable Prognosis in Suboptimal Surgery in High-Grade Serous Ovarian Carcinoma
by Hiroshi Harada, Toru Hachisuga, Yoshikazu Harada, Mami Shibahara, Midori Murakami, Fariza Nuratdinova, Shota Higami, Atsushi Tohyama, Yasuyuki Kinjo, Taeko Ueda, Tomoko Kurita, Yusuke Matsuura, Toshiyuki Nakayama and Kiyoshi Yoshino
Diagnostics 2025, 15(4), 422; https://doi.org/10.3390/diagnostics15040422 - 10 Feb 2025
Viewed by 562
Abstract
Background: The immunoreactive (IR) subtype is one of the subtypes of high-grade serous ovarian carcinoma (HGSOC) with intra-tumoral lymphocytic infiltration. A positive prognostic correlation between IR subtype and R0 + optimal surgery has been reported. This study investigates the prognostic significance of tumor-infiltrating [...] Read more.
Background: The immunoreactive (IR) subtype is one of the subtypes of high-grade serous ovarian carcinoma (HGSOC) with intra-tumoral lymphocytic infiltration. A positive prognostic correlation between IR subtype and R0 + optimal surgery has been reported. This study investigates the prognostic significance of tumor-infiltrating lymphocytes (TILs) in the suboptimal surgery group of HGSOCs. Methods: After reviewing 318 malignant ovarian tumors detected in our database between 2000 and 2017, 74 HGSOCs with supplemental p53 immunostaining were selected. Differences in progression-free survival (PFS) and overall survival (OS) between the two groups of the IR subtype and the other subtypes were investigated. Based on pathological findings, HGSOCs were divided into two groups: those with or without abundant TILs. Results: Abundant TILs were detected in 17 cases of HGSOC (22.9%). Clinicopathological characteristics including age, CA125, FIGO stage, and residual disease did not show significant differences between the two groups. Lymph node metastasis was more common in the IR subtype group (p = 0.04). In the suboptimal surgery group, the 5-year PFS and OS (Kaplan–Meier estimates) in cases with (n = 10) or without (n = 21) abundant TILs were 10% and 0% (p = 0.097) and 70% and 28.5% (p = 0.012), respectively. The median time (range) to OS in cases with or without abundant TILs were 58 (34–81) months and 39 (22–55) months, respectively. Multivariate analysis in OS showed significant differences in TILs. Conclusions: Abundant intra-tumoral lymphocytic infiltration is an independent and favorable prognostic indicator for the suboptimal surgery group in HGSOCs and is associated with treatment response via cancer immunity. Full article
(This article belongs to the Special Issue Histopathologic Diagnosis in Surgical Oncology)
Show Figures

Figure 1

Back to TopTop